Exclusivity Patents and exclusivity Drug Information Prescribing and other information DMFs Type 2 master files Databases Free access to database search 21 CFR FDA regulations for this API Federal Register FR search results for this API Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823/S3 01/05/01 05/09/03 Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823 4/21/00 8/16/01 4/24/00 10/11/01 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type Exelon (rivastigmine tartrate) Solution, 2 mg/mL, Novartis NDA 21-025 4/21/00 4/24/00 4/24/00 4/11/02 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon (RIVASTIGMINE), Novartis Pharmaceuticals | Exelon (rivastigmine) capsules, Novartis Pharma, Labeling Revision | Exelon (rivastigmine) oral solution, Novartis Pharma, Labeling Revision | Rivastigmine Tartrate Capsule, Watson Labs, Tentative Approval | Rivastigmine Tartrate Oral Solution, Ranbaxy Labs, Tentative Approval | Rivastigmine Tartrate Capsules, Sun Pharma, Tentative Approval | Rivastigmine Tartrate Capsules, Dr. Reddy’s Labs, Tentative Approval | Exelon (rivastigmine) Capsules, Novartis Pharma, New or Modified Indication | Exelon (rivastigmine) Liquid, Novartis Pharma, New or Modified Indication Check the most up-to-date list of FDA Approvals.                                                                                      A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | FindingHealthOnline © 2009 Betterchem.com